DOJ, SEC issue subpoena to Johnson & Johnson over baby product safety
By Nikita Chaurasia  Date: 2019-02-26

DOJ, SEC issue subpoena to Johnson & Johnson over baby product safety

Johnson & Johnson is presently facing lawsuits involving 13,000 plaintiffs.

Pharmaceutical and consumer products giant Johnson & Johnson has confirmed that it has received subpoenas from the U.S. Department of Justice as well as the Securities and Exchange Commission (SEC), with regard to investigations into alleged asbestos contamination in the products from its well-known Baby Powder line.

Apparently, the company aims to fully cooperate with inquiries from the authorities and would keep defending itself against talc product-related litigation. In its annual report issued recently, the company accepted for the first time that it had received subpoenas from U.S. agencies over safety concerns regarding its talc power products, Reuters has mentioned. 

The DOJ and SEC did not seem to have offered any comments for responding to the news. 

A report released in December said that Johnson & Johnson was aware for decades that asbestos, which is a recognized carcinogen, had been found several times in its talc and powder products in small amounts. The company had allegedly failed to disclose this information, found out from tests conducted from 1970s to early 2000s, to the public and the regulators.

Records show that the information revealed had led to Johnson & Johnson shares losing about $40 billion from the market valuation in a single day. It had also triggered a public relations disaster involving worldwide inquiries about probable health effects of its signature product.

For its part, the company has stated that inquiries from federal agencies are based on news reports which consisted of inaccurate statements, besides withholding vital information that were made public already. Johnson & Johnson has insisted that for decades, independent testing performed by regulators and leading laboratories around the world have proven its baby power is asbestos-free, safe to use and does not cause cancer.

For the record, Johnson & Johnson is facing lawsuits involving 13,000 plaintiffs who claim using the company’s talc products, such as Baby Powder, have caused cancer.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...